MALIC ACID

/static/temp/default.svg

Search structure


Synonyms	Apple acid D,l-malic acid Dl-malic acid E-296 E296 FEMA NO. 2655 Hydroxybutanedioic acid Hydroxybutanedioic acid, (-)- Hydroxysuccinnic acid (-) INS NO. 296 INS NO.296 INS-296 L-malate L-malic acid Malate Malic acid Malic acid l-(-)-form Malic acid, dl- Malic acid, l- NSC-25941 NSC-9232 Pomalous acid Salivix
Status
Molecule Category	Free-form
UNII	817L1N4CKP
EPA CompTox	DTXSID0027640


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	BJEPYKJPYRNKOW-UHFFFAOYSA-N
Smiles	O=C(O)CC(O)C(=O)O
InChI	InChI=1S/C4H6O5/c5-2(4(8)9)1-3(6)7/h2,5H,1H2,(H,6,7)(H,8,9)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C4H6O5
Molecular Weight	134.09
AlogP	-1.09
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	3.0
Polar Surface Area	94.83
Molecular species	ACID
Aromatic Rings	0.0
Heavy Atoms	9.0

Assay Description	Organism	Bioactivity	Reference
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	5.57 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	7.0 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.01 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.01 %

Cross References

Resources	Reference
ChEBI	6650
ChEMBL	CHEMBL1455497
DrugBank	DB12751
FDA SRS	817L1N4CKP
Human Metabolome Database	HMDB0000744
Guide to Pharmacology	2480
KEGG	C00711
PubChem	525
SureChEMBL	SCHEMBL856

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).